Literature DB >> 25842072

Hepatocellular carcinoma: present and future.

Gaetano Bertino1.   

Abstract

Entities:  

Year:  2012        PMID： 25842072     DOI： 10.3978/j.issn.2304-3865.2012.09.02

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN： 2304-3865


× No keyword cloud information.
  5 in total

1.  In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.

Authors:  Shaomei Yang; Bo Zhang; Xiaowei Gong; Tianqi Wang; Yongjun Liu; Na Zhang
Journal:  Int J Nanomedicine       Date:  2016-05-25

2.  Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.

Authors:  Chung-Feng Huang; Ming-Lun Yeh; Cing-Yi Huang; Pei-Chien Tsai; Yu-Min Ko; Kuan-Yu Chen; Zu-Yau Lin; Shinn-Cherng Chen; Chia-Yen Dai; Wan-Long Chuang; Jee-Fu Huang; Ming-Lung Yu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

3.  Network of clinically-relevant lncRNAs-mRNAs associated with prognosis of hepatocellular carcinoma patients.

Authors:  Lee Jin Lim; Yu Jin; Henry Yang; Alexander Y F Chung; Brian K P Goh; Pierce K H Chow; Chung Yip Chan; William K Blanks; Peng Chung Cheow; Ser Yee Lee; Tony K H Lim; Samuel S Chong; London L P J Ooi; Caroline G Lee
Journal:  Sci Rep       Date:  2020-07-07       Impact factor: 4.379

4.  NRAGE is a potential diagnostic biomarker of hepatocellular carcinoma.

Authors:  Wenshuang Zou; Junfeng Cui; Zhong Ren; Yan Leng
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

5.  Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.

Authors:  Ahmed M Afifi; Ahmed M El-Husseiny; Reda H Tabashy; Mohamed A Khalil; Motawa E El-Houseini
Journal:  Asian Pac J Cancer Prev       Date:  2019-10-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.